Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CP-870,893 + Tremelimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CP-870,893||CD40 Antibody 8||CP-870,893 is a monoclonal antibody that binds CD40 and acts as an agonist, which potentially results in enhanced immune response and tumor growth inhibition (PMID: 21479995).|
|Tremelimumab||CP-675,206|Ticilimumab|CP-675206||CTLA4 Antibody 17 Immune Checkpoint Inhibitor 94||Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||CP-870,893 + Tremelimumab||Phase I||Actionable||In a Phase I trial, the combination of CP-870,893 and Tremelimumab was well-tolerated, and metastatic melanoma patients treated with CP-870,893 and Tremelimumab combination therapy demonstrated an objective response rate of 27.3% (6/22; 2 complete and 4 partial responses), a median progression-free survival of 3.2 months, and median overall survival of 23.6 months, with a 45-month median follow-up (PMID: 30288340; NCT01103635).||30288340|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|